The Russian-made vaccine posts competitive phase III data – but not on the easily stored formulation.
Relief as two further pandemic vaccines succeed, but the data confirm variants to be a problem.
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.